Bicycle Therapeutics Ltd has recruited Nicholas Keen to the role of chief scientific officer to oversee development of its peptide-based therapeutics for cancer. Dr Keen was previously head of oncology research at the Novartis biomedical research institute in Cambridge, Massachusetts, US. Prior to this, he worked in oncology research at AstraZeneca Plc with a focus on epigenetic regulation.
Dr Keen earned a BA in natural sciences and a PhD in virology and cancer biology at the University of Cambridge in the UK. He completed his post-doctoral training in transcriptional biology at the MRC Laboratory of Molecular Biology.
Bicycle Therapeutics announced the appointment on 5 January 2017.
Copyright 2017 Evernow Publishing Ltd